Investigation of awareness of human papilloma virus infection among female health workers at Ondokuz Mayıs University

Abstract

Less developed areas have the highest incidence rates of cervical cancer, which vary by geographic region. If the right lifestyle changes are made, all cervical cancer risk factors can be avoided. Furthermore, vaccines have been created to guard against a number of the high-risk strains of the human papillomavirus (HPV). Not all women are aware of cervical cancer or how to prevent it, even though it is preventable. Therefore, every woman must assess level of knowledge regarding HPV prevention and cervical cancer. We applied a validated questionnaire between January and June 2021 to the female health workers at Ondokuz Mayıs University Hospital to assess their knowledge of cervical cancer and HPV protection as well as their attitudes toward it. Our findings indicate that women's knowledge on this topic is lacking, especially regarding the most recent advancements in HPV testing and vaccination-based cervical cancer prevention. Only 99% of the women who responded to the survey were actually aware that HPV testing was available. Although the incidence of cervical cancer is low, this figure is subject to change, particularly in light of the economic crisis and rising immigration rates, which could lead to higher rates of HPV infection in the population if no action is taken. Although the HPV vaccine has been available for some time, the Turkish government does not recommend it as a routine vaccine as part of the National Immunization Program. Even among the highly educated workforce in the healthcare industry, there is a lack of understanding about HPV vaccine. Healthcare professionals should be fully informed about the HPV vaccine for their own benefit so that they can discuss it with their patients. This study aimed to remove vaccination barriers and assess healthcare professionals' current knowledge of cervical cancer and HPV vaccination in a tertiary hospital.

Keywords

• Hpv
• Cervical cancer
• Smear
• cervical pathology

References

1. 1) Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med. 2020 Dec;20(6):186. doi: 10.3892/etm.2020.9316. Epub 2020 Oct 13. PMID: 33101476; PMCID: PMC7579832.
2. 2) Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019;15(1):146-155. doi: 10.1080/21645515.2018.1512453. Epub 2018 Sep 6. PMID: 30148974; PMCID: PMC6363146.
3. 3) Mladěnka A, Sláma J. Vaccination against HPV and view of new possibilities. Ceska Gynekol. 2018 Winter;83(3):218-225. English. PMID: 30764623.
4. 4) Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, Scaduto G, Firenze A, Vassiliadis A, Perino A. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother. 2017 Aug 3;13(8):1839-1843. doi: 10.1080/21645515.2017.1319026. Epub 2017 Jun 8. PMID: 28594305; PMCID: PMC5557238.
5. 5) Gohar A, Abdeltawab NF, Shehata N, Amin MA. Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries. Papillomavirus Res. 2019 Dec;8:100172. doi: 10.1016/j.pvr.2019.100172. Epub 2019 Jun 8. PMID: 31185296; PMCID: PMC6586776.
6. 6) Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608. doi: 10.1080/01443615.2019.1634030. Epub 2019 Sep 10. Erratum in: J Obstet Gynaecol. 2020 May;40(4):590. PMID: 31500479; PMCID: PMC7062568.
7. 7) Fields EJ, Hopfer S, Warren JR, BeLue R, Lebed J, Hecht ML. Motivators and Barriers to HPV Vaccination: A Qualitative Study of Underserved Women Attending Planned Parenthood. Vaccines (Basel). 2022 Jul 15;10(7):1126. doi: 10.3390/vaccines10071126. PMID: 35891290; PMCID: PMC9317585.
8. 8) Roland KB, Benard VB, Greek A, Hawkins NA, Saraiya M. Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers. Vaccine. 2014 Sep 22;32(42):5432-5. doi: 10.1016/j.vaccine.2014.07.098. Epub 2014 Aug 12. PMID: 25131744; PMCID: PMC4480766.

9. 9) Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic review. Hum Vaccin Immunother. 2016 Jun 2;12(6):1454-68. doi: 10.1080/21645515.2015.1129090. Epub 2016 Feb 2. PMID: 26838681; PMCID: PMC4964733.
10. 10) Khosa LA, Meyer JC, Motshwane FMM, Dochez C, Burnett RJ. Vaccine Hesitancy Drives Low Human Papillomavirus Vaccination Coverage in Girls Attending Public Schools in South Africa. Front Public Health. 2022 May 24;10:860809. doi: 10.3389/fpubh.2022.860809. PMID: 35685759; PMCID: PMC9171038.
11. 11) Berkowitz Z, Nair N, Saraiya M. Providers' practice, recommendations and beliefs about HPV vaccination and their adherence to guidelines about the use of HPV testing, 2007 to 2010. Prev Med. 2016 Jun;87:128-131. doi: 10.1016/j.ypmed.2016.02.030. Epub 2016 Feb 26. PMID: 26921654; PMCID: PMC6343123.
12. 12) Kechagias KS, Kalliala I, Bowden SJ, Athanasiou A, Paraskevaidi M, Paraskevaidis E, Dillner J, Nieminen P, Strander B, Sasieni P, Veroniki AA, Kyrgiou M. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ. 2022 Aug 3;378:e070135. doi: 10.1136/bmj-2022-070135. PMID: 35922074; PMCID: PMC9347010.